ClinicalTrials.gg
Active, not recruitingNCT03916627Updated Apr 6, 2026

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

A Phase 2 interventional study of cemiplimab and Platinum Doublet in Non-small Cell Lung Cancer, Hepatocellular Carcinoma and Head and Neck Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
12th of 29
65 · median 61
Started
2019
the only one that year
Phase 2
19 of 29
13 open now
Primary completion
2025-03
later than 0 of 21 live
Registered
6th of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 19 in phase 2, reaches primary completion later than 0 of the 21 other live ones, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study drug" or "study drugs" when combined.

Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins naturally found in your blood that fight infections. A monoclonal antibody is a special kind of antibody that is manufactured as a medication to target specific proteins in the body that may be involved in your cancer.

  • Cemiplimab is a drug that blocks the programmed death receptor 1 (PD-1), a cell receptor on immune cells
  • Fianlimab is a drug that blocks the action of a protein called lymphocyte activation gene (LAG)-33 (LAG-3)
03

Conditions studied

  • Non-small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Head and Neck Squamous Cell Carcinoma

Keywords

  • NSCLC
  • HCC
  • HNSCC
  • Resectable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient must have a known diagnosis of NSCLC, HCC, or HNSCC as defined in the protocol
  • Patient must be willing and able to provide blood samples at the indicated time points
  • Patient must be willing and able to have excisional or core needle of tumor prior to initiation of cemiplimab as defined in the protocol
  • (ECOG) performance status of 0 or 1
  • Patient is determined to be a surgical candidate for resection of their tumor
  • Adequate organ and bone marrow function as defined in the protocol

Key Exclusion Criteria:

  • Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor
  • Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery
  • Patients who have participated in a study of an agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)
  • Patients who have had major surgery within 14 days prior to initiation of Therapy
  • Patients with disease for whom the intent of surgery would not be curative
  • Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator
  • Is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment
  • Has active disease that has required systemic treatment in the past 1 year
  • Has a known, additional that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.
  • Encephalitis, meningitis, or uncontrolled seizures in the year prior to
  • History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.
  • Uncontrolled infection with (HIV), or infection (HCV); or diagnosis of immunodeficiency as defined in the protocol
  • NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.
  • NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.

Note: Other protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Cohort A1

    Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual

    Drug: cemiplimab · Drug: Platinum Doublet

  • Experimental
    Cohort A2

    Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual

    Drug: cemiplimab · Drug: Platinum Doublet

  • Experimental
    Cohort A3

    Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual

    Drug: cemiplimab · Drug: Platinum Doublet

  • Experimental
    Cohort B

    Cemiplimab prior to surgery; cemiplimab post surgery (HCC)

    Drug: cemiplimab

  • Experimental
    Cohort C

    Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) Not open for accrual

    Drug: cemiplimab

  • Experimental
    Cohort B2

    SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)

    Drug: cemiplimab

  • Experimental
    Cohort B3

    Cemiplimab and fianlimab before and after surgery (HCC)

    Drug: cemiplimab · Drug: fianlimab

Interventions

  • Administered intravenous (IV)

    Also known as: REGN2810, Libtayo

  • DrugPlatinum Doublet

    Administered intravenous (IV)

  • Administered IV

    Also known as: REGN3767

06

What researchers measure

Primary outcomes

  1. Major pathologic response (MPR) at time of surgery for the NSCLC cohorts

    Cohorts A1, A2, A3

    Time frame: At time of surgery

  2. Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohorts

    Cohort B, B2, B3

    Time frame: At time of surgery

  3. Major treatment effect (MTE) at time of surgery is the primary endpoint for the HNSCC cohort

    Cohort C

    Time frame: At time of surgery

Secondary outcomes

  1. Delay to surgery

    Defined as surgery \>28 days following the end of the second cycle of cohort specific neoadjuvant therapy

    Time frame: Surgery >28 days following the end of the cycle of last dose of cemiplimab

  2. Event-free survival (EFS)

    Defined as the time from the first study treatment to the date of disease progression that precluded definitive surgery, or recurrence of tumor after successful surgery, or death from any cause.

    Time frame: Up to 60 months following surgery

  3. Disease-free survival (DFS)

    Defined as the time from date of surgery until recurrence of tumor or death from any cause after successful surgery and recovery

    Time frame: Up to 60 months following surgery

  4. Overall response rate (ORR)

    Defined as the percent of patients with a complete response (CR) or partial response (PR) documented by the Investigator per RECIST 1.1. as described in the protocol

    Time frame: Up to 60 months following surgery

  5. Overall survival (OS)

    Defined as the time from the first study treatment and date of death for any reason

    Time frame: Up to 60 months following surgery

  6. OS rate

    Time frame: 12 months

  7. OS rate

    Time frame: 18 months

  8. OS rate

    Time frame: 24 months

  9. OS rate

    Time frame: 36 months

  10. OS rate

    Time frame: 48 months

  11. OS rate

    Time frame: 60 months

  12. Incidence of treatment emergent adverse events (TEAEs)

    Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)

    Time frame: Up to 60 months following surgery

  13. Incidence of imAEs

    Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)

    Time frame: Up to 60 months following surgery

  14. Incidence of SAEs

    Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)

    Time frame: Up to 60 months following surgery

  15. Incidence of deaths

    Time frame: Up to 60 months following surgery

  16. Incidence of laboratory abnormalities

    Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)

    Time frame: Up to 60 months following surgery

  17. Change in tumor-infiltrating CD8 T-cell density

    Defined as the change from baseline to the time of surgery

    Time frame: Baseline to time of surgery

07

Study locations

1 site
08

References and documents

Publications

  • D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. PubMed 39437804 ↗
  • Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20. PubMed 35065058 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Mar 2025, 68 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 68 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
Apr 16, 2019
StartActual
Jul 23, 2019
Primary completionActual
Mar 31, 2025
CompletionEst.
May 14, 2030
Results delay requested
Mar 30, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03916627
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Jul 23, 2019
Primary completion
Mar 31, 2025
Completion
May 14, 2030 (estimated)
Last update
Apr 6, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion